Filing Flows › Teva Pharmaceutical Industries (TEVA) › Gross margin
Teva Pharmaceutical Industries (TEVA) gross margin by quarter
Teva Pharmaceutical Industries' gross margin was 55.5% in Q3 2026 (third quarter 2026), +6.0 pts from Q1 2026. Over the last 6 quarters it ranged from 48.2% (Q1 2025) to 56.4% (Q4 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 55.5% | +6.0 pts | +4.1 pts |
| Q1 2026 | 49.5% | -6.9 pts | +1.3 pts |
| Q4 2025 | 56.4% | +5.0 pts | — |
| Q3 2025 | 51.4% | +1.1 pts | — |
| Q2 2025 | 50.3% | +2.1 pts | — |
| Q1 2025 | 48.2% | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' gross margin?
Teva Pharmaceutical Industries' gross margin was 55.5% in Q3 2026 (third quarter 2026), +6.0 pts from Q1 2026.
How has Teva Pharmaceutical Industries' gross margin changed?
Over the last 6 quarters it ranged from 48.2% (Q1 2025) to 56.4% (Q4 2025).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →